1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,540 | 0,590 | 12.05. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.05. | RECBIO-B Completes Full Circulation of H Shares | 1 | AASTOCKS | ||
| 30.04. | RECBIO-B (02179): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 30.04. | RECBIO-B (02179): INSIDE INFORMATION ANNOUNCEMENT COMPLETION OF FULL CIRCULATION OF H SHARES | 3 | HKEx | ||
| 29.04. | RECBIO-B (02179): FORM OF PROXY FOR USE AT THE 2025 ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, MAY 28, 2026 | - | HKEx | ||
| JIANGSU RECBIO TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 29.04. | RECBIO-B (02179): NOTICE OF 2025 ANNUAL GENERAL MEETING | - | HKEx | ||
| 29.04. | RECBIO-B (02179): CIRCULAR OF 2025 ANNUAL GENERAL MEETING | - | HKEx | ||
| 29.04. | RECBIO-B (02179): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 29.04. | RECBIO-B (02179): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 24.03. | RECBIO-B (02179): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 AND PROPOSED CHANGE OF THE USE OF PROCEEDS | 1 | HKEx | ||
| 24.03. | RECBIO-B (02179): CHANGE OF JOINT COMPANY SECRETARIES, AUTHORISED REPRESENTATIVE AND PROCESS AGENT | 1 | HKEx | ||
| 12.03. | RECBIO-B (02179): DATE OF BOARD MEETING | - | HKEx | ||
| 06.02. | RECBIO-B (02179): INSIDE INFORMATION ANNOUNCEMENT GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE FOR THE H SHARE FULL CIRCULATION PLAN OF THE COMPANY | 1 | HKEx | ||
| 30.01. | RECBIO-B (02179): INSIDE INFORMATION ANNOUNCEMENT ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION PLAN OF THE COMPANY | 1 | HKEx | ||
| 29.12.25 | RECBIO-B (02179): VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF THE NEW DRUG APPLICATION FOR THE COMPANY'S NOVEL ADJUVANTED RECOMBINANT SHINGLES VACCINE REC610 ... | 2 | HKEx | ||
| 23.12.25 | RECBIO-B (02179): CHANGE OF THE CHAIRMAN OF THE BOARD OF DIRECTORS AND ADJUSTMENT TO THE COMPOSITION OF THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 19.12.25 | RECBIO-B (02179): RULES OF PROCEDURE FOR THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 19.12.25 | RECBIO-B (02179): RULES OF PROCEDURE FOR THE GENERAL MEETINGS | 1 | HKEx | ||
| 19.12.25 | RECBIO-B (02179): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 19.12.25 | RECBIO-B (02179): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 19.12.25 | RECBIO-B (02179): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 19, 2025; AMENDMENTS TO THE ARTICLES OF ASSOCIATION; ABOLISHMENT ... | 1 | HKEx |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,95 | -1,07 % | Aktien im Fokus - LPKF Laser: Party bald vorbei? - BioNTech, BVB, Elmos, Rheinmetall und Verbio | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| OCUGEN | 1,270 | +1,11 % | Ocugen Aktie explodiert nach unten: Wie tief geht es noch? | ||
| VIKING THERAPEUTICS | 26,950 | +0,94 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| INFLARX | 2,268 | +8,41 % | InflaRx schwenkt auf Nierenerkrankungen - 150 Mio. Dollar frisches Kapital | InflaRx will den oralen C5a-Rezeptor-Inhibitor Izicopan künftig vorrangig in der ANCA-assoziierten Vaskulitis entwickeln, einer lebensbedrohlichen Nierenerkrankung. Für Izicopan läuft die Phase-2-Planung... ► Artikel lesen | |
| EDITAS MEDICINE | 2,480 | -0,80 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 16,100 | -1,23 % | Sarepta tumbles as its gene therapy sales decline further | ||
| CARDIOL THERAPEUTICS | 1,172 | +1,38 % | Cardiol Therapeutics Inc: Cardiol to publish phase II Maveric results in JAHA | ||
| BASILEA | 60,20 | -1,47 % | Basilea Pharmaceutica International Ltd, Allschwil: Basilea-Aktionäre genehmigen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats | Allschwil, 15. April 2026
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 66,22 | -1,66 % | Arrowhead anticipates SHASTA-3/4 topline in Q3 while planning an SHTG sNDA before end of 2026 | ||
| TELIX PHARMACEUTICALS | 9,119 | +3,06 % | TELIX PHARMACEUTICALS LIMITED: Change in substantial holding | ||
| ONCO-INNOVATIONS | 0,670 | -2,62 % | Onco-Innovations meldet Forschungszusammenarbeit von Inka Health zur Förderung der Nachweiserzeugung in der Onkologie | Vancouver, Kanada - 5. Mai 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") freut sich bekannt zu geben, dass Inka... ► Artikel lesen | |
| TWIST BIOSCIENCE | 47,820 | +0,36 % | LenioBio GmbH: LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery | LenioBio GmbH, a TechBio company commercializing its ALiCE cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will... ► Artikel lesen | |
| REPLIGEN | 94,38 | -2,44 % | Barclays Maintains an "Overweight Rating" on Repligen Corporation (RGEN) | ||
| UNIQURE | 24,200 | -2,42 % | FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next? | ||
| PHARMAMAR | 97,55 | 0,00 % | PharmaMar looks to accelerate oncology research with AI through collaboration with Globant | The new alliance has launched a multi-agent AI framework to support faster, data-driven decisions in cancer research.
Agentic AI system achieves 15x faster insights with over 90% accuracy.... ► Artikel lesen |
JIANGSU RECBIO TECHNOLOGY CO LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JIANGSU RECBIO TECHNOLOGY CO LTD finden Sie auf Wallstreet Online.